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Serious concerns regarding a meta-analysis of preexposure prophylaxis use and STI acquisition
An article in AIDS by Kojima and colleagues posits that
high unadjusted rates for sexually transmitted infections
(STIs) among preexposure prophylaxis (PrEP) users in
five studies, compared with low unadjusted rates for PrEP
nonusers in 14 studies [1], reflect increased sexual risk
behaviors following PrEP uptake. They conclude with a
call to reconsider how this important HIV prevention
strategy is implemented.
Distortions of these findings were disseminated by
activists opposing widespread PrEP implementation.
One large provider of HIV treatment and testing services,
summarized the research letter as ‘a damning new
report. . .showing a dangerous link between the usage of
PrEP by MSM and an astronomical increase in STIs [2].’
In an effort to understand more about the claims of
Kojima et al. [1], we reviewed the data and the analyses
and found several serious problems.
First, Kojima et al. [1] presented only unadjusted analyses
comparing PrEP users and nonusers from different studies.
The findings only indicate higher STI rates in the PrEP-
using compared with the non-PrEP-using samples, not an
increased rate of STIs. These PrEP-using and non-PrEP-
using samples also differ in their distributions of other
factors associated with STI acquisition, including year,
race/ethnicity, sex, HIV status, and age [3,4].
STI incidence for men who have sex with men (MSM)
has seen dramatic increases in the past decade that may
help explain the findings [4]. Condomless anal sex (CAS)
among MSM also increased from 2005 to 2014 [5]. Four
of five PrEP studies were published in 2015–2016,
whereas all but two non-PrEP studies were published
before 2015. Kojima et al. [1] did not address the increases
in STI incidence and CAS that predated widespread PrEP
availability. We further note that although PrEP avail-
ability has expanded recently, uptake remains low among
some groups with elevated rates of STIs, including MSM
of color [6,7]. In other words, factors other than PrEP
may explain both increases in STI rates and differences
among MSM groups.
Second, Kojima et al. [1] included the EXPLORE study
for which they indicated 36 628 person-years of
observation and an ‘any STI’ rate of 5.8/100 person-
years (http://links.lww.com/QAD/A944). Inclusion of
this massive study disproportionately influenced the
overall non-PrEP STI rate estimate of 6.4 per 100 years
despite the higher incidence rates in the other much
smaller studies of non-PrEP users.
More problematic is that EXPLORE did not fit the
inclusion criterion of Kojima et al. [1] for studies with
‘incidence rates reported with nucleic amplification
testing.’ Per EXPLORE investigator, Beryl Koblin,
PhD (personal communication, 11 October 2016),
EXPLORE ceased testing for bacterial STIs within its
first year. EXPLORE only collected self-reports of new
STIs, and its published reports are limited to self-reported
chlamydia and gonorrhea cases at baseline. Furthermore,
EXPLORE followed participants for a total of 12 240
person-years [8], not the 36 628 person-years provided
(http://links.lww.com/QAD/A944).
Third, adding to the inflated risk ratio estimates caused by
incorrect EXPLORE data, the letter includes inconsist-
ent data for at least two other studies. For the PROUD
study, Kojima et al. [1] report 276 and 124 incident STI
cases for PrEP users and nonusers, respectively. The
published article lists 210 cases for PrEP users and 165 for
nonusers, not to mention different numbers of person-
years [9]. The data of Kojima et al. [1] referencing the
study by Burchell et al. [10] of HIV-positive, non-PrEP
users also have incorrect estimates of MSM gonorrhea
and chlamydia cases and person-years of observation for
the minority who actually received STI testing.
When we recalculated the overall STI rates excluding
EXPLORE and using the published numbers of incident
STIs and person-years for PROUD, the STI rate in non-
PrEP users versus PrEP users was 22.8/100 person-years
versus 63.4/100 person-years. The data of Kojima et al.
[1] yield estimates of 5.8/100 person-years versus
67.7/100 person-years in non-PrEP users versus users.
Although the recalculated non-PrEP rate is still lower, the
less extreme difference in STI rates is less prone to being
sensationalized than the inflated estimate of Kojima et al.
[1]. All of the data reported by Kojima et al. [1] warrant
vetting and reanalyses.
Finally, persons on PrEP are monitored more closely and
tested more frequently for STIs than non-PrEP users;
however, Kojima et al. [1] do not adjust for this difference.
The PROUD study, which did control for more frequent
monitoring of PrEP users, did not find statistically
significant differences in STI rates compared with a
concurrently observed delayed control group. Further-
more, the immediate PrEP intervention group acquired
significantly fewer new HIV infections despite greater
frequency of receptive CAS [9]. This point of effective
HIV prevention was not mentioned by Kojima et al. [1]
and was downplayed by subsequent media.
ISSN 0269-9370 Copyright Q 2017 Wolters Kluwer Health, Inc. All rights reserved. 739
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Exaggerated and incorrect data on negative potential
outcomes of PrEP use may discourage PrEP’s consider-
ation as an HIV prevention strategy. We need more
evidence-based interventions to reduce STIs, not
abandonment of a highly effective HIV prevention
method. Indeed, it is critically important for HIV
researchers to pursue how best to harness PrEP for the
welfare of those at highest risk of HIV, while minimizing
potential risks. We also need more STI prevention
interventions, improved diagnostic and surveillance
capacity, and increased STI funding. Scientific inquiry
to estimate accurately relative STI rates among compar-
able groups of PrEP users and nonusers is relevant to both
goals but must be carried out in a rigorous manner
accounting for alternate explanations.
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Addressing concerns regarding preexposure prophylaxis meta-analysis
We appreciate the commentary [1] about our analysis and
agree that preexposure prophylaxis (PrEP) for HIV is
a critical strategy for the prevention of acquisition of
HIV infection. The authors of the commentary [1]
acknowledge the importance of our findings; however,
they raise concerns that our findings might partially be
explained by the overall general increase in incidence of
sexually transmitted infections (STIs) among MSM
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